


# Cancer Medicines Outcome Project (CMOP)

Professor Marion Bennie
University of Strathclyde
Collaborative Programme with NHS
GG&C funded by Scottish Government

#### **Aims**

- To co-ordinate an incremental program of planned studies to test the connectivity and linkage of current and evolving local and national datasets to determine clinical outcome data for cancer medicines.
- To test the feasibility of collecting and analysing quality of life data from clinical practice, aligned to the early exemplar studies, to inform a potential enhanced data strategy for collection and analysis of patient reported outcome measures (PROMs).



# **Qualitative** Work Stream

#### Year one exemplar projects



#### Prostate Cancer

- Abiraterone and Enzalutamide
- Baseline characteristics including PS,
   co-morbidities
- Outcomes: duration of therapy, stop reason, OS, time to PSA progression, time to chemo/radio, Opiate prescribing
- PROMs

#### Melanoma

- BRAF inhibitors/MEK inhibitors and immunotherapy
- Baseline characteristics including
   BRAF status, depcat score,
   prognostic scores, co-morbidities
- Outcomes: duration of therapy, OS,
   stop reason, toxicities including
   supportive meds and hospital
   admissions

## Patient Reported Outcome Measures (PROMs)



- Real life impact of these medicines on patients' quality of life (positive and negative) – not routinely captured.
- Examine the utility of adoption and /or adaption of recognised measures of general and disease specific quality of life tools into clinical practice.
- Identify PROMs tools already used in clinical practice
- What is useful / practical for patients / clinicians? Barriers?
- How can inclusion of PROMs in addition to clinical outcomes supports improved decision making?

## Qualitative Methodological Approach



TASK 1: Scope & Focus-Setting TASK 2: Application of PROMs in Clinical Practice

TASK 3: Selecting a Tool to Test (Prostate)

TASK 4: Melanoma Work Stream

<b>TASK 1</b>	<b>TASK 2</b>	<b>TASK 3</b>	TASK 4
(April 2017)	(May 2017)	(Nov 2017)	(TBC)
Agree scope & approach of PROMs work stream	Collate and map use of PROMs applied in clinical practice globally	<ul> <li>Literature         review of         validated tools</li> <li>Qualitative         data collection         with         stakeholder         groups</li> <li>Analysis &amp;         Write-Up</li> </ul>	<ul> <li>Literature         review of         validated tools</li> <li>Qualitative         data collection         with         stakeholder         groups</li> <li>Analysis &amp;         Write-Up</li> </ul>

## 3 Main Tool Types



## General QoL

- SF-36 / SF12
- EQ5D

## Cancerfocused

- EORTC QLQ-C30
- FACT

## Diseasefocused

- EPIC-26
- QLQ-PR25
- FACT-P
- FACT-M
- Skindex-16

Μ

P

## Matrix of PROMS Applications in Cancer



Degree of PROMs collection implementation

Service-Based Applications
/
Early-Stage Disease

Service-Based Applications
/
Survival / Post-Event


Pilot-Based Applications
/
Early-Stage Disease

Pilot-Based Applications
/
Survival / Post-Event

#### General Health QoL Items:








#### **Disease-Specific** QoL Items: Prostate Tools





#### **Disease-Specific** QoL Items: Melanoma Tools

	Site Pain	Swelling	Movement	Skin Changes	Numbness	Itching	Burning / Stinging	Irritation	Persistence	Skin appearance	Headaches	Fevers	Stomach Swelling	
FACT-M														
Skindex-														
	1	1	1	1	1	1	1	1	1	2	1	1	1	1

# Key Points & Observations



- Literature details pilots, projects, new tool development or reliability/validity testing
- Prostate literature far more rich than melanoma
- Generic tools identified in cancer cover work, pain, and anxiety/stress most:
- Most applications are project-based and not service-integrated
- Most applications focus on *survival / post-events* and not on the disease trajectory
- Details on tools / tool development not always available
- NHS-based PROMs applications for event-based interventions and not part of practice for all